Article

Inspire Pharmaceuticals to commercialize InSite Vision antibiotic if approved

Durham, NC-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.’s 1% azithromycin topical anti-infective product (AzaSite) in the United States and Canada under the terms of a licensing agreement signed by the two companies. The product is under new device application review by the FDA for the treatment of bacterial conjunctivitis.

Durham, NC-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.’s 1% azithromycin topical anti-infective product (AzaSite) in the United States and Canada under the terms of a licensing agreement signed by the two companies. The product is under new device application review by the FDA for the treatment of bacterial conjunctivitis.

The broad-spectrum antibiotic is formulated with InSite’s patented drug-delivery vehicle (DuraSite). If approved, it is anticipated that the product will become the first ocular antibiotic with a once-daily dosing regimen after an initial loading dose. The companies say the dosing schedule may increase patient adherence and therapeutic efficacy.

The agreement calls for Inspire to pay InSite an upfront license fee of $13 million and an additional $19 million payment contingent on regulatory approval by the FDA. Inspire also will pay a royalty-20% on net sales in the first 2 years of commercialization and 25% thereafter-on net sales of the antibiotic in the United States and Canada, if approved by regulatory authorities.

The collaboration “will allow us to pursue additional anti-infective products and indications worldwide,” said S. Kumar Chandrasekaran, PhD, chief executive officer of InSite, based in Alameda, CA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
© 2025 MJH Life Sciences

All rights reserved.